We propose that aged c-Kit+ cardiac progenitor cells (CPCs) actively secrete extracellular vesicles enriched in miR-34a that enforce a senescent state on neighboring progenitors, thereby linking tumor suppressor pathways to regenerative restraint as an evolved antagonistic pleiotropy (AP) mechanism. This vesicular miR-34a suppresses SIRT1, stabilizes p53, and sustains the SASP, creating a feedback loop that limits progenitor expansion while reducing oncogenic risk early in life. In later life, the same loop becomes maladaptive, driving stem cell exhaustion and impaired cardiac repair. Key predictions: (1) inhibiting neutral sphingomyelinase-2 (nSMase2)-dependent vesicle release in aged mice will increase c-Kit+ CPC proliferation and improve post-injury regeneration without elevating tumor incidence up to 18 months of age; (2) prolonged inhibition beyond 24 months will lead to a measurable increase in cardiac neoplasms, revealing the age-dependent trade-off; (3) vesicle-derived miR-34a levels in coronary effluent will correlate inversely with cardiac functional recovery after myocardial infarction across the lifespan.

**Experimental design

• Use inducible, CPC-specific nSMase2 knockout (cKit-CreERT2; nSMase2fl/fl) mice. Treat young (3 mo), middle-aged (12 mo) and old (24 mo) cohorts with tamoxifen, then subject to permanent left anterior descending ligation.
• Assess CPC proliferation (Ki-67+/c-Kit+), senescence (beta-gal, p16), fibrosis (Masson’s trichrome), and ejection fraction by echocardiography at 7 days and 28 days post-injury.
• Monitor spontaneous tumor formation in the heart and off-target organs up to 30 months.
• Isolate circulating extracellular vesicles; quantify miR-34a by qPCR and SIRT1/p53 levels in recipient CPCs in vitro.

**Expected outcomes and falsifiability

If the hypothesis is correct, nSMase2 loss will rescue CPC proliferative capacity and improve functional recovery in 12-mo mice without increasing tumorigenesis, whereas the same intervention in 24-mo mice will show enhanced regeneration accompanied by a rise in precancerous lesions, demonstrating the AP trade-off. Failure to observe age-dependent differences in tumor onset, or a lack of regenerative improvement despite vesicle blockade, would falsify the proposed mechanism. Conversely, a uniform increase in tumors across all ages would suggest the vesicular pathway is not a selected AP trait but a generic stress response.

**Broader implications

This framework reframes cardiac progenitor aging as a tunable, intercellular communication system shaped by selection rather than passive damage. Therapeutic strategies could transiently modulate vesicle biogenesis to harness regenerative potential while monitoring oncologic safety, aligning longevity medicine with the evolutionary logic that shaped senescence.